CRTC1-TRIM11: A Novel Oncogenic Driver in Cutaneous Tumors – From Molecular Pathways to Therapeutic Target

The CRTC1 fusion gene has recently been identified as a novel oncogenic driver in cutaneous tumors, presenting new insights into tumorigenesis and potential therapeutic targets. This fusion results from a translocation involving the CRTC1 transcriptional coactivator and the TRIM11 ubiquitin E3 ligase, leading to the dysregulation of key cellular processes such as proliferation, apoptosis, and differentiation. The aberrant activation of signaling pathways by the CRTC1 fusion promotes unchecked cellular growth, contributing to the formation and progression of malignant lesions in the skin. Because the fusion gene affects protein degradation and cellular signaling, it is clear that it plays a role in cancer development. This means that it could be a key target for therapy. Current research is focused on elucidating the molecular mechanisms by which CRTC1 drives tumor growth, intending to identify specific pathways that novel treatments can target. Inhibition of these pathways or disrupting the fusion gene's expression holds promise for developing more effective therapies.